Literature DB >> 7016550

Double-blind trial comparing guanfacine and methyldopa in patients with essential hypertension.

A J Bune, J P Chalmers, J R Graham, P R Howe, M J West, L M Wing.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7016550     DOI： 10.1007/bf00544579

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  12 in total

1.  A sensitive radioenzymatic assay for norepinephrine in tissues and plasma.

Authors:  D P Henry; B J Starman; D G Johnson; R H Williams
Journal:  Life Sci       Date:  1975-02-01       Impact factor: 5.037

2.  Rebound hypertension after acute methyldopa withdrawal.

Authors:  A C Burden; C P Alexander
Journal:  Br Med J       Date:  1976-05-01

3.  Rebound hypertension after sudden discontinuation of methyldopa therapy.

Authors:  D B Frewin; R K Penhall
Journal:  Med J Aust       Date:  1977-04-30       Impact factor: 7.738

4.  A new centrally action antihypertensive agent guanfacine (BS 100-141).

Authors:  U C Dubach; R Huwyler; P Radielovic; M Singeisen
Journal:  Arzneimittelforschung       Date:  1977

5.  The peripheral circulatory effects of clonidine and their role in the production of arterial hypotension.

Authors:  J Shaw; S N Hunyor; P I Korner
Journal:  Eur J Pharmacol       Date:  1971-04       Impact factor: 4.432

6.  Comparative haemodynamic effects of clonidine and guanfacine.

Authors:  H F Oates; L M Stoker; E P MacCarthy; J C Monaghan; G S Stokes
Journal:  Arch Int Pharmacodyn Ther       Date:  1978-01

7.  The effects of treatment and of withdrawal of treatment with guanfacine and clonidine on blood pressure and heart rate in normotensive and renal hypertensive rats.

Authors:  R Salzmann
Journal:  J Pharm Pharmacol       Date:  1979-04       Impact factor: 3.765

8.  Pharmacological actions of the antihypertensive agent N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride (BS 100-141).

Authors:  G Scholtysik; H Lauener; E Eichenberger; H Bürki; R Salzmann; E Müller-Schweinitzer; R Waite
Journal:  Arzneimittelforschung       Date:  1975-10

9.  Effects of clonidine withdrawal: possible mechanisms and suggestions for management.

Authors:  S N Hunyor; L Hansson; T S Harrison; S W Hoobler
Journal:  Br Med J       Date:  1973-04-28

10.  Clonidine withdrawal in hypertension. Changes in blood-pressure and plasma and urinary noradrenaline.

Authors:  J L Reid; L M Wing; H J Dargie; C A Hamilton; D S Davies; C T Dollery
Journal:  Lancet       Date:  1977-06-04       Impact factor: 79.321
View more
  3 in total

1.  Guanfacine and clonidine: antihypertensive and withdrawal characteristics after continuous infusion and its interruption in the spontaneously hypertensive and normotensive rat.

Authors:  M J Thoolen; P B Timmermans; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-04       Impact factor: 3.000

Review 2.  Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-04       Impact factor: 9.546

Review 3.  Methyldopa for primary hypertension.

Authors:  Greg T Mah; Aaron M Tejani; Vijaya M Musini
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.